First Mid Bancshares Q1 EPS $0.96 Up From $0.88 YoY

First Mid Bancshares (NASDAQ:FMBH) reported quarterly earnings of $0.96 per share. This is a 9.09 percent increase over earnings of $0.88 per share from the same period last year.

byBenzinga Newsdesk

April 27, 2022

1 minute read

First Mid Bancshares (NASDAQ:FMBH) reported quarterly earnings of $0.96 per share. This is a 9.09 percent increase over earnings of $0.88 per share from the same period last year.

Bitcoin, Ethereum, Dogecoin Slide: Analyst Warns Of ‘Very Volatile’ Week Ahead

By Shivdeep Dhaliwal

Today, 11:59 AM

Major coins showed weakness Sunday evening as the global cryptocurrency market cap shrunk 1.4% to $922.5 billion at 8:05 p.m. EDT.

$DOGE

Vipshop Sputters, But Stays Focused on Brand-Name Discounts

By The Bamboo Works

Today, 11:59 AM

Key takeaways: After years of steady growth, Vipshop posted a rare 5% revenue decline in its latest quarter, with profit down by an even sharper 42% The discount e-commerce company has rolled out a series of initiatives to jumpstart growth, including trying to convert more users into VIP members By Trevor MO

BABA

Cannabis Movers & Shakers: Curaleaf Holdings, TREES, Dewey Scientific, The Flowr Corporation

By Jelena Martinovic

Today, 11:59 AM

Curaleaf Holdings’ Shareholders Elect Directors Cannabis company Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) announced that its shareholders elected directors at its annual and special meeting held on Thursday, September 9.

CANN

Oncology-Focused Biotech Immuneering Jumps To Wall Street With $112M IPO

By Vandana Singh

Today, 11:59 AM

Immuneering Corp (NASDAQ:IMRX) has kept a relatively low profile since launching with $17 million back in 2019. That is until…

FPX

First Mid Bancshares Q1 EPS $0.96 Up From $0.88 YoY

Related Posts

Bitcoin, Ethereum, Dogecoin Slide: Analyst Warns Of ‘Very Volatile’ Week Ahead

Vipshop Sputters, But Stays Focused on Brand-Name Discounts

Cannabis Movers & Shakers: Curaleaf Holdings, TREES, Dewey Scientific, The Flowr Corporation

Oncology-Focused Biotech Immuneering Jumps To Wall Street With $112M IPO